



Voyager Therapeutics to Present at Upcoming Investor Conferences

05/11/16

CAMBRIDGE, Mass., May 11, 2016 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced that company management will present at the following upcoming investor conferences in New York City:

- **Piper Jaffray GenomeRx Symposium**
Date: Tuesday, May 17, 2016
Panel 1 Title: *Thinking Smart About CNS Targeting Gene Therapy*
Time: 11:20 a.m. ET
Panel 2 Title: *Manufacturing, Automating, Scaling Up*
Time: 2:15 p.m. ET
- **2016 UBS Global Healthcare Conference**
Date: Monday, May 23, 2016
Time: 8:30 a.m. ET
- **Jefferies 2016 Global Healthcare Conference**
Date: Tuesday, June 7, 2016
Time: 8:30 a.m. ET

Live-streaming webcasts of company presentations at the UBS and Jefferies Global Healthcare Conferences can be accessed through the Investors & Media section of Voyager's website at www.voyagertherapeutics.com. Webcasts will be archived for 30 days after the live events conclude.

About Voyager Therapeutics

Voyager Therapeutics is a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system. Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. The company's pipeline is focused on severe CNS diseases in need of effective new therapies, including advanced Parkinson's disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich's ataxia, Huntington's disease, spinal muscular atrophy (SMA), frontotemporal dementia, Alzheimer's disease and severe, chronic pain. Voyager has broad strategic collaborations with Sanofi Genzyme, the specialty care global business unit of Sanofi, and the University of Massachusetts Medical School. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts. For more information, please visit www.voyagertherapeutics.com. Follow Voyager on [LinkedIn](#).

Investor Relations & Media Contact:

Matt Osborne

Head of Investor Relations & Corporate Communications

857-259-5353 ☐

mosborne@vygr.com



Voyager Therapeutics